Search the Newsreel

Why Alphatec Holdings (ATEC) Is Up 5.9% After Reaffirming 2026 Outlook And Narrowing Q2 Losses

Alphatec Holdings (ATEC) saw its stock rise 5.9% after reporting narrowed Q2 net losses and reaffirming its 2026 revenue guidance of approximately US$882 million. The company also filed a shelf registration for 800,000 common shares. This performance highlights Alphatec's cost discipline and continued investment …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Phathom Pharmaceuticals, Inc. (PHAT) after the company lowered its full-year 2026 net revenue guidance, contradicting earlier affirmations. The investigation focuses on whether the company made misleading statements to investors regarding its financial outlook and …

Paradeep Phosphates incorporates Fertilizer Innovation Foundation–India

ATEC Stock Price and Chart — NASDAQ:ATEC

This article provides a detailed overview of Alphatec Holdings, Inc. (NASDAQ:ATEC) stock, including its current price, historical performance, key financial metrics, and analyst ratings. It highlights the company's focus on spinal fusion technology and reports its Q2 2026 earnings, showing revenue growth and increased …

Alphatec (ATEC) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026, at 4:30 p.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer - Patrick MilesExecutive Vice President and Chief Financial Officer - J. Todd Koning TAKEAWAYS Total Revenue -- $214 million in the second quarter, …

HC Wainwright Cuts Earnings Estimates for Alphatec

HC Wainwright has reduced its FY2027 earnings per share (EPS) estimate for Alphatec to $0.47 from $0.59, while reiterating a "Buy" rating and a $24 price target. This revision follows Alphatec's recent quarterly earnings which met EPS expectations of $0.07 and surpassed revenue forecasts …

Hennion & Walsh Asset Management Inc. Has $3.55 Million Stake in Phathom Pharmaceuticals, Inc. $PHAT

Hennion & Walsh Asset Management Inc. significantly increased its stake in Phathom Pharmaceuticals (NASDAQ:PHAT) by 124.3% in Q2, now holding 327,278 shares valued at $3.55 million. Other institutional investors like Millennium Management and Invesco have also expanded their positions, with institutional holdings making up …

Phathom Pharmaceuticals, Inc. Investigated by the Portnoy Law Firm

The Portnoy Law Firm has initiated an investigation into Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) for possible securities fraud. This investigation follows Phathom's recent downward revision of its full-year 2026 revenue expectations, despite earlier assurances of significant sales force expansion and a projected $1 billion …

Renaissance Technologies LLC Acquires New Holdings in Phathom Pharmaceuticals, Inc. $PHAT

Renaissance Technologies LLC has acquired a new position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), purchasing 305,800 shares valued at approximately $3.4 million during the first quarter. This makes Renaissance Technologies LLC one of several institutional investors, who collectively own 99.01% of PHAT, to increase their …

Alphatec Holdings (ATEC) Earnings And Guidance Keep Valuation In Focus

Alphatec Holdings general counsel sells $78,821 in ATEC shares

Tyson Eliot Marshall, General Counsel of Alphatec Holdings (NASDAQ:ATEC), sold 8,168 shares for a total of $78,821 to cover tax withholding obligations from vested restricted stock units. This sale was conducted under a Rule 10b5-1 trading plan. Despite the stock being down 56% year-to-date, …

Insider Selling: Alphatec (NASDAQ:ATEC) General Counsel Sells 8,168 Shares

Alphatec (NASDAQ:ATEC) General Counsel Tyson Eliot Marshall sold 8,168 shares of the company's stock, valued at $78,821.20, on August 5th. This transaction was part of a pre-arranged Rule 10b5-1 plan to cover tax withholding obligations from vested equity awards. Despite this insider sale, Alphatec …

Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Alphatec Holdings recently reported its second-quarter earnings, leading to analysts updating their price targets and earnings forecasts for the company. While sales beat expectations, earnings per share missed targets, resulting in a slight reduction in the consensus price target. The article examines the sentiment …

ETFs Investing in Alphatec Holdings, Inc. Stocks

This article lists various ETFs that invest in Alphatec Holdings, Inc. (ATEC) stocks, providing details such as market value, weight, issuer, management style, focus, expense ratio, AUM, price, and performance metrics for each fund. The funds primarily target small-cap and healthcare sectors, indicating ATEC's …

What Alphatec Holdings (ATEC)'s Reaffirmed 2026 Outlook and Narrowing Losses Mean For Shareholders

Alphatec Holdings (ATEC) has reported its Q2 and H1 2026 results, showing reduced net losses and reaffirming its full-year 2026 revenue guidance of approximately US$882 million. This positive outlook, driven by increasing surgeon adoption and procedural volumes, supports the company's investment narrative toward profitability …

Narrower Losses And Reaffirmed 2026 Revenue Guidance Might Change The Case For Investing In Alphatec Holdings (ATEC)

Alphatec Holdings, Inc. recently reported past second-quarter 2026 results showing its net loss narrowed to US$25.78 million, or US$0.16 per share, and reaffirmed full-year 2026 revenue guidance of about US$882 million, including US$805 million of surgical revenue and US$77 million of EOS revenue. Alongside …

Phathom Pharmaceuticals, Inc. (PHAT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) shareholders after the company lowered its full-year 2026 net revenue guidance. This reduction followed earlier affirmations of higher revenue projections by company executives. Shareholders are encouraged to contact …

Alphatec Holdings, Inc. $ATEC Shares Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC significantly increased its stake in Alphatec Holdings, Inc. ($ATEC) by 21.3% in the first quarter of 2026, acquiring an additional 184,969 shares and bringing its total holdings to over 1 million shares. Other institutional investors also boosted their positions in the …

Alphatec Holdings (ATEC) Stock Sinks As Margin Gains Fail To Convince

Alphatec Holdings' stock (ATEC) dropped 7.5% despite reporting improved Q2 2026 results, including narrowed losses, increased revenue, and higher adjusted EBITDA with a 17% margin. While the company showed strong surgeon adoption and operating leverage, investors remain concerned about execution risks with new products …

(ATEC) Risk Channels and Responsive Allocation

This article provides an AI-driven analysis of Alphatec Holdings Inc. (NASDAQ: ATEC), highlighting a strong near-to-mid-term sentiment but a weak long-term outlook. It identifies an exceptional 185.0:1 risk-reward setup targeting a 43.3% gain against a 0.2% risk and outlines specific position, momentum, and risk-hedging …

Alphatec Holdings, Inc. SEC Filing (Aug 5, 2026)

Alphatec Holdings, Inc. (ATEC) filed a Form 144 with the SEC on August 5, 2026, indicating a proposed sale of securities. The filing details the sale of 8,168 common shares with an aggregate market value of $84,538.80, acquired on the same date as Restricted …

Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuticals, Inc. (PHAT) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Phathom Pharmaceuticals, Inc. (PHAT) on behalf of investors. This investigation follows Phathom's announcement of lowered full-year 2026 net revenue guidance, contradicting earlier reaffirmations by company executives. The firm encourages affected investors to contact them …

UBS Adjusts Price Target on Alphatec Holdings to $16 From $15, Maintains Buy Rating

UBS has increased its price target for Alphatec Holdings (ATEC) to $16 from $15, while reaffirming a Buy rating on the stock. This adjustment reflects the analyst's updated outlook for the medical device company. Alphatec Holdings specializes in technology for spinal disorder treatment and …

Alphatec Holdings, Inc. Stock 12‑Month Price Target Raised to $16.07, Implies 55% Upside

Analysts have raised the 12-month price target for Alphatec Holdings, Inc. stock to $16.07, up from $15.86, with forecasts ranging from $12 to $24 per share. This new target suggests a potential upside of approximately 55% based on the August 4 closing price. The …

Alphatec Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ATEC) 2026-08-05

Alphatec reported strong Q2 2026 results, with revenue up 15% to $214 million and adjusted EBITDA up 53% to $36 million, driven by increased surgical adoption and procedural volume. The company generated positive free cash flow and raised its full-year adjusted EBITDA guidance to …

Alphatec Holdings Inc (ATEC) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ...

This article first appeared on GuruFocus. Release Date: August 04, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Alphatec Holdings Inc (NASDAQ:ATEC) delivered strong financial results in Q2 2026, with total revenue of …

ATEC Q2 2026 slides: profitability growth outpaces revenue gains

Alphatec Holdings Inc. (ATEC) reported strong Q2 2026 financial results, with adjusted EBITDA surging 53% to $36 million on 15% revenue growth to $214 million, significantly outpacing Wall Street expectations for revenue. Despite strong operational performance and increased profitability, the stock declined 2.96% after …

Alphatec Holdings (NASDAQ:ATEC) Shares Dip Slightly After In-Line Q2 Results

Alphatec Holdings (NASDAQ:ATEC) reported Q2 2026 revenue of $213.5 million and non-GAAP EPS of $0.07, aligning with analyst estimates. Despite in-line results and a 15% year-over-year revenue increase, shares experienced a slight dip after hours, likely due to full-year revenue guidance remaining below consensus. …

Alphatec Holdings (Nasdaq: ATEC) lifts 2026 EBITDA outlook after Q2

Alphatec Holdings (ATEC) reported strong Q2 2026 results, with total revenue up 15% year-over-year to $214 million and adjusted EBITDA reaching $36 million. The company reaffirmed its full-year 2026 revenue guidance of $882 million and raised its adjusted EBITDA outlook from $134 million to …

ATEC Reports Second Quarter Financial Results

Total revenue of $214 million, up 15% year-over-year Surgical revenue of $196 million increased 17%, driven by 20% case volume growth Company reaffirms 2026 revenue outlook CARLSBAD, Calif., August 04, 2026--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to …

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 5.5% - Here's Why

Alphatec earnings up next: Can spine disruptor ease growth fears? By Investing.com

Alphatec Holdings Inc. is set to report second-quarter earnings, with analysts keenly watching if its growth momentum can alleviate investor concerns about its surgical revenue trajectory. Despite all 14 analysts rating the stock a buy with a 56% implied upside, EPS estimates have slightly …

Earnings Flash (ATEC) Alphatec Holdings, Inc. Reports Q2 Revenue $213.5M, vs. FactSet Est of $211.3M

Alphatec Holdings, Inc. (ATEC) announced its Q2 revenue reached $213.5 million, surpassing the FactSet estimate of $211.3 million. The company reaffirmed its earnings guidance for the full-year 2026. This positive financial update follows several recent analyst initiations and price target adjustments for Alphatec Holdings.